Summit Therapeutics (SMMT) Leases (2019 - 2025)
Historic Leases for Summit Therapeutics (SMMT) over the last 7 years, with Q3 2025 value amounting to $5.4 million.
- Summit Therapeutics' Leases fell 3204.61% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 3204.61%. This contributed to the annual value of $7.1 million for FY2024, which is 2193.21% up from last year.
- Latest data reveals that Summit Therapeutics reported Leases of $5.4 million as of Q3 2025, which was down 3204.61% from $5.6 million recorded in Q2 2025.
- Summit Therapeutics' 5-year Leases high stood at $9.4 million for Q1 2024, and its period low was $1.5 million during Q1 2021.
- In the last 5 years, Summit Therapeutics' Leases had a median value of $5.4 million in 2025 and averaged $5.0 million.
- Per our database at Business Quant, Summit Therapeutics' Leases soared by 40361.01% in 2021 and then crashed by 3630.11% in 2025.
- Quarter analysis of 5 years shows Summit Therapeutics' Leases stood at $2.8 million in 2021, then surged by 49.64% to $4.2 million in 2022, then skyrocketed by 40.34% to $5.9 million in 2023, then grew by 21.93% to $7.1 million in 2024, then fell by 24.13% to $5.4 million in 2025.
- Its Leases was $5.4 million in Q3 2025, compared to $5.6 million in Q2 2025 and $6.4 million in Q1 2025.